Extended Dose Ipilimumab With a Peptide Vaccine: Immune Correlates Associated With Clinical Benefit in Patients With Resected High-Risk Stage IIIc/IV Melanoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-10-2463
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)


Related search